On November 12, 2025 SOTIO Biotech, a clinical-stage biopharmaceutical company owned by PPF Group, reported favorable preclinical results supporting the development of SOT106, its antibody-drug conjugate for the treatment of sarcoma, at the Connective Tissue Oncology Society (CTOS) Annual Meeting taking place November 12-15, 2025, in Boca Raton, FL.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Data presented in SOTIO’s poster indicate that SOT106 is a potent and well-tolerated LRRC15-targeted ADC, showing strong potential for the treatment of sarcomas and other LRRC15-positive malignancies.
Specific results include:
SOT106 induces potent, antigen-specific cytotoxicity in vitro with nanomolar activity and a pronounced bystander effect.
In vivo, SOT106 drives dose-dependent tumor regression, including complete responses at 1 mg/kg, and surpasses benchmarks in both soft tissue sarcoma and osteosarcoma patient-derived xenograft (PDX) models, including those with low-to-medium LRRC15 expression and in orthotopic osteosarcoma.
In an exploratory non-human primate (NHP) study, SOT106 had a favorable pharmacokinetic profile and a high therapeutic index; dose-limiting toxicities aligned with known MMAE effects.
"Sarcomas continue to represent a significant unmet medical need, with limited therapeutic progress over the past several decades. LRRC15 is a clinically validated target broadly expressed across sarcoma subtypes, making it an ideal candidate for a differentiated ADC approach," said Amy Jensen-Smith, chief scientific officer of SOTIO. "These NHP data reinforce our confidence in SOT106’s therapeutic potential and mark a critical step toward delivering a novel treatment option for patients facing these aggressive diseases."
SOTIO is advancing SOT106 through IND-enabling studies toward an anticipated IND filing in Q4 2026. The company has additionally developed and validated a proprietary, highly sensitive, and specific LRRC15 immunohistochemistry assay to guide patient selection in upcoming clinical trials.
Poster presentation and Q&A details:
Poster Title: "Targeting leucine-rich repeat-containing protein 15 (LRRC15): SOT106 antibody-drug conjugate for soft tissue sarcoma and osteosarcoma treatment"
Presenter: Lenka Palova Jelinkova, Ph.D.
Date & Time: Thursday, Nov. 13, 2025, 5:30-6:30pm EST
Location: Grand Ballroom, The Boca Raton
Presentation materials will be available upon request following the live presentations.
(Press release, SOTIO, NOV 12, 2025, View Source [SID1234659858])